Overview of the 2020 ASH guidelines for transfusion support in SCD

Stella T. Chou, MD

The Children's Hospital of Philadelphia Perelman School of Medicine at the University of Pennsylvania South Thames Sickle Cell and Thalassemia meeting

February 24, 2021





No conflicts of interest to disclose



Clinical Guidelines

American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support

Stella T. Chou, Mouaz Alsawas, Ross M. Fasano, Joshua J. Field, Jeanne E. Hendrickson, Jo Howard, Michelle Kameka, Janet Kwiatkowski, France Pirenne, Patricia A. Shi, Sean R. Stowell, Swee Lay Thein, Connie M. Westhoff, Trisha E. Wong, Elie A. Akl

https://ashpublications.org/bloodadvances/article/4/2/327/440607

<text><text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text></text>	CLINICAL GUIDELI	NES	© blood advances
Start J. Chou, ¹ Mouze Alaewas, ² Rose M. Fasano, ⁹ Jortun J. Field, ⁴ Jearne E. Hendrickson, ⁴ D. Howard, ⁷⁴ Michel Kamele, ⁸ Jane J. Kwiskowski, ¹ France Firmero, ¹⁰ Patricia A. Shi, ¹¹ Sun R. Showal, ⁸ Swee Lay Thein, ¹² Cornie M. Westhoff, ¹¹ Traha E. Wang, and D. Alae. Their of Hendricky, Children Hendrick, ¹⁰ Kocheter, ¹⁰ Kristowski, ¹⁰ Genero, ¹⁰ Hendrick,	American Socie transfusion sup	ty of Hematology 20 port	020 guidelines for sickle cell disease:
<text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text>	Stella T. Chou, ¹ Mouaz Alsav Janet L. Kwiatkowski, ¹ France and Elie A. Akl ¹⁵	vas, ² Ross M. Fasano, ³ Joshua J. Fie 9 Pirenne, ¹⁰ Patricia A. Shi, ¹¹ Sean R	kl, ⁴ Jeanne E. Hendrickson, ^{5,6} Jo Howard, ^{7,8} Michelle Kameka, ⁹ . Stowell, ³ Swee Lay Thein, ¹² Connie M. Westhoff, ¹³ Trisha E. Wong. ¹
Background: Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease. (SOD), but pose significant clinical challenges. Guidance for specific indications and administration, transfusion reactions (DHTRa), and iron overload may improve outcomes. Objective: Our objective was to dawlop evidence-based guidelines to support patients, clinicians, and tother hatthcase professions about transfusion support for SOD and the management transfusion-related complications. Methods: The American Society of Hematology formed a multidisciplinary panel that was balanced minimize bis from conflicts of interest and that included a patient representative. The panel pionitade clinic questions and outcomes. The Mayo Clinic Evidence Based Practice Research Program supported if guideline development process. The Grading of Rocommendations Avissement, Development an Exatuation GRADE approach was used to form recommendations, which were subject to public comment provention, and management of alloimmunization, DHTRs, and iron overload. Conclusions: The majority of panel recommendations evolution due to the paucity of direct, hig outering vidence of cardiogry genotypic red coll matching, the mochanism of HTRs ensultir rom specific alloantigens to inform therapy, the role and timing of regular transfusions during programory women, and the optimal treatment of transfusional iron overload in SCD. Summary of recommendations, work, end of end diverse effects, including adjormunization, and management of all antimization, and management of allowing optimal treatment of transfusions and underson therapy or policie diverse for specific alloantigens to inform therapy, the role and timing of regular transfusions during programory women, and the optimal treatment of transfusion and iron overload in SCD. Summary of the optimal treatment of transfusion and into overbaa (SCD). Rod cell transfusions are used in the acute and chronic management of many complication related to SCD, but ar	¹ Division of Hematology, Children's H Practice Research Program, Mayo Cl School of Medicine, Atlants, GA, 'Dago University School of Medicine, New Has Thomas' NHS Foundation Taut, Londo Laboratory of Excellence, French Blood Institutes of Health, Betheada, MD, ¹¹ U Pediatrice, Oregon Health and Science	loophai of Philadelphia, Perefman School of Me link, Rochester, MN: ⁹ Center for Translasion a remoter of Medican Medica College of Walcomi era, CIT: ⁹ Department of Harmatological Medicine , Nobel Kingdow, "Nobol Wethinson: College of Establishment, Orietal, Fancor, ¹¹ New York Blood aboatary of Immunohematology and Genomical University, Forder J. College and College (University, Forder), College and College (University, College), College and College (University, College), College), College (University, College), Colleg	dicine at the University of Pennsylvania, Philadejhia, PA; ⁵ Mayo Cinic Evidence-Based of Cahluir Therary, Department of Pathology and Laboratory Medicine, Ennoy University , Marulae, NY, ⁵ Opartment of Laboratory Medicine and ⁵ Department of Pelaetrika, Yele (Krigh Callege London, London, Linhed Kingdon, [*] Department of Heatmativage, Gayie and Sk. Naving and Heaht Biolence, Riodik Intermisional University, Ware, FL; [*] 1985/ENU4986, Onater, New York, NY, ¹⁶ Stable Call Branch, National Heart, Lung, and Bilood Institute, National lew York Biood Center, New York, NY, ¹⁶ Stable Call Branch, Dalico at Heartabarg, Calavage, Dapatment of ani Medicina, Aneonic Minestry of Marin, Bahru, Labano.
Objective: Our objective was to develop evidence-based guidelines to support patients, clinicians, ar other heit/hare professionals in their decisions about translusion support for SCD and the management translusion-related complications. Methods: The American Society of Hematology formed a multidisciplinary panel that was balanced minimize bias from conflicts of interest and that included a patient prosessment, Development at a Valation (GRADDE approach was used to form recommendations, which were subject to public commer a Valation (GRADDE approach was used to form recommendations, which were subject to public commer fractations, and mode of administration (simple varied cell antigen typing and matchin indications, and mode of administration (simple varied cell antigen typing and matchin indications, and mode of administration (simple varied cell antigen typing and matchin indications, and mode of administration (simple varied cell antigen typing and matchin indications, and mode of administration (simple varied cell antiching, the mechanism of HTRs result for support of subject is public or outcomes of interest. Research priorities were identified, induding prospecific aloadigens to inform therapy, the role and timing of regular translusions during prognancy for owner, and the optimal treatment of translusional iron overload in SCD. Summary of recommendations Example developed 10 recommendations were constitued approxement of adjointee as the optimal treatment of translusional iron overload in SCD. Summary of recommendations Example developed 10 recommendations were constitued approxement of patients with sickle cell disease (SCD). Red cell translusions are used in the acute and timing of regular translusions during prognatory of more the optimal treatment of translusion support remains a key intervention in the ma		Background: Red cell transf (SCD), but pose significant di transfusion, as well as screeni transfusion reactions (DHTRs)	usions remain a mainstay of therapy for patients with sickle cell disease nical challenges. Guidance for specific indications and administration o ng, prevention, and management of alloirmnurization, delayed hemolytic , and iron overload may improve outcomes.
Methods: The American Society of Hematology formed a multidisciplinary panel that was balanced minimize bias from conflicts of interest and that included a patient representative. The panel provided fill guideline development process. The Grading of Recommendations Assessment, Development at a Evaluation (GRADE) approach was used to form recommendations, which were subject to public commendations, and mode of administration (simple varied cell exchange), as well as screenin prevention, and management of alloimmunization, DHTRs, and iron overfoad. Conclusions: The majority of panel recommendations were conditional due to the paucity of direct, hig ortainty evidence for outcomes of interest. Research priorities were identified, including prospecific alloadingens to inform therapy, the role and timing of mguter transfusions during pregnancyf women, and the optimal treatment of alloimmunization, DHTRs, and iron overfoad. Summary of recommendations Summary of patients were conditional due to the paucity of direct, hig ortainty evidence for avolg over genotypic red ool matching, the molenaim of HTRs ensult from specific alloadigens to inform therapy, the role and timing of mguter transfusions during pregnancyf women, and the optimal treatment of transfusional iron overfoad in SCD. Summary of recommendations Subject to public do SCD, but are not without ddworese effects, including alloimmunization and iron overfoad (SCD). Rod cell transfusions are used in the acute and chronic management of may complication continue to SCD, but are not without ddworese effects, including alloimmunization and iron overfoad Specific indications, mode of red cell antigen typing and matching, transfusion malated to the follow areas: extent of red cell antigen typing and matching, transfusion made of administration, and transfusion mode of administration, and transfusion metaded		Objective: Our objective was other healthcare professionals in transfusion-related complication	to develop evidence-based guidelines to support patients, clinicians, and their decisions about transfusion support for SCD and the management o s.
Results: The panel developed 10 recommendations focused on red cell antigen typing and matchin indications, and management of alloimmization, DHTRs, and iron overload. Conclusions: The majority of panel recommendations were constituted due to the paucity of direct, hig ortainty evidence for outcomes of interest. Research priorities were identified, including prospecific studies to understand therete of serologics vs genotypic red cell matching, the mechanism of HTRs result from specific alloantigens to inform therapy, the role and timing of regular transfusions during program of women, and the optimal treatment of transfusional iron overload in SCD). Role of transfusions are used in the acute and chronic management of patients with sickle cell diseas (SCD). Role cell transfusions are used in the acute and chronic management of may complexed relation support remains a key intervention in the management of patients with sickle cell diseas (SCD). Role cell transfusions are used in the acute and chronic management of these quicklens. Transfusion support remains a key intervention in the management of these quicklens or values of SCD). Discole of transfusions are used in the acute and chronic management of these quicklens. Transfusion support remains a key intervention in the management of these quicklens. The value of the SCD, but are not without daverse effects, including aloimmunization and iron overlaes Specific indications, mode of red cell administration, and transfusion related complications continue to pose significant challenges for patients and providers, and are the focus of these quicklenses. American Society of Hermatokogy (ASH guideline panel addressed specific questions matked to the follow areas: extent of red cell antigen typing and matching, transfusion indications and mode of administration Submitted 28 October 2019; published online 27		Methods: The American Soc minimize bias from conflicts of in questions and outcomes. The guideline development proces Evaluation (GRADE) approach	iety of Hernatology formed a multidisciplinary panel that was balanced to terest and that included a patient representative. The panel prioritized cinica Mayo Cinic Evidence-Based Practice Research Program supported th thes. The Grading of Recommendations Assessment, Development and was used to form recommendations, which were subject to public comment
Conclusions: The majority of panel recommendations were conditional due to the paucity of direct, hig containty evidence for outcomes of interest. Research priorities were identified, including prospector studies to understand thereof serologic vs genotypic red coll matching, the mechanism of HTRs result from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy f women, and the optimal treatment of transfusional iron overload in SCD. Summary of recommendations Background Transfusion support remains a key intervention in the management of patients with sickle coll diseast (SCD). Rod coll transfusions are used in the acute and chronic management of may complication related to SCD, but are not without devices effects, including alloimmunization and iron overloa Specific indications, mode of red cell administration, and transfusion related to the followis areas: extent of red cell angles for patients and providens; and are the focus of these guidelines. Tr American Society of Hermatology (ASH guideline panel addressed specific unclations evidenders areas: extent of red cell angles for patients and providens; and are the focus of these guidelines. Submitted 28 October 2019; sublished online 27 The full-text version of this article contains a data supplement.		Results: The panel developed indications, and mode of a prevention, and management	I 10 recommendations focused on red cell antigen typing and matching dministration (simple vs red cell exchange), as well as screening of alkimmunization, DHTRs, and iron overload.
Summary of recommendations Background Transfusion support remains a key intervention in the management of patients with sickle cell disease (SCD). Red cell transfusions are used in the acute and chronic management of many complication related to SCD, but are not without davores effects, including alloimmunization and iron overbas Specific indications, mode of red cell administration, and transfusion related complications contains to pose significant challenges for patients and providers, and are the focus of these guidelines. Tr American Society of Hematology (ASH guideline panel addressed specific questions related to the followic areas: extent of red cell angles hyping and matching, transfusion indications and mode of administration Submitted 28 October 2019; subgitted 20 November 2019; published online 27 The full-text version of this article contains a data supplement.		Conclusions: The majority of certainty evidence for outcom studies to understand the role or from specific alloaningers to inf women, and the optimal treatment women and the optimal treatment of the statement of the statement women and the optimal treatment statement of the statement of the statement of the statement of the statement of the statement o	panel recommendations were conditional due to the paucity of direct, high es of interest. Research priorities were identified, including prospective servologics agenotypic et coll anatching, the mechanism of HTHs resulting rm thempy, the role and timing of regular transfusions during pregnancy fo ent of transfusional iron overload in SCD.
Background Transfusion support remains a key intervention in the management of patients with sickle cell disear (SCD). Rod cell transfusions are used in the acute and chronic management of many complication related to SCD, but are not without daverse effects, including alloimmunization and iron overbas Specific indications, mode of rod cell administration, and transfusion and iron overbas Specific indications, mode of rod cell administration, and transfusion related complications continu- to pose significant challenges for patients and providers, and are the focus of these guidelines. IT American Society of Hematology (ASH guideline panel addressed specific questions related to the followin areas: extent of red cell artigen typing and matching, transfusion indications and mode of administration Submitted 28 October 2019; subsidied online 27 Submitted 28 October 2019; subsidied online 27 The full-text version of this article contains a data supplement.		Summary of recomm	nendations
Transfusion support remains a key intervention in the management of patients with sickle cell diseas (SCD). Red cell transfusions are used in the acute and chronic management of many complication related to SCD, but are not without devoires effects, including alloimmunization and iron overbas Specific indications, mode of red cell administration, and transfusion related complications continu- to pose significant challenges for patients and providers, and are the focus of these guidelines. It American Society of Hermatology (ASH guideline panel addressed specific questions related to the followir areas: extent of red cell antigen typing and matching, transfusion indications and mode of administratio Submitted 28 October 2019; societed 20 November 2019; published online 27 The full-text version of this article contains a data supplement.		Background	
Submitted 28 October 2018; accepted 20 November 2018; published online 27 The full-test version of this article contains a data supplement. January 2020. DOI 10.1182/bb/odu/emnes.2018001148.		Transfusion support remains a (SCD), Red cell transfusions related to SCD, but are not Specific indications, mode of to pose significant challenges American Society of Hematolog areas: extent of red cell antige	key intervention in the management of patients with sickle cell disease are used in the acute and chronic management of many complications without adverse effects, including alloimmunization and iron overload red cell administration, and transfusion-related complications continue for patients and providers, and are the focus of these guidelines. The (ASH) guideline panel addressed specific questions related to the following hybrig and matching, transfusion indications and mode of administration
	Submitted 28 October 2019; accept January 2020. DOI 10.1182/bloodad	ed 20 November 2019; published online 27 vances.2019001143.	The full-test version of this article contains a data supplement.
28 JANUARY 2020 • VOLUME & NUMBER 2			



How were these ASH guidelines developed?

PANEL FORMATION

Each guideline panel was formed following these key criteria:

- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of conflicts of interest

CLINICAL QUESTIONS

10 clinically-relevant questions generated in PICO format (population, intervention, comparison, outcome)

Example: PICO question

"Should automated red cell exchange vs simple transfusion or manual red cell exchange be used for patients with SCD receiving chronic transfusions?"

EVIDENCE SYNTHESIS

Evidence summary generated for each PICO question via systematic review of health effects plus:

- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

MAKING RECOMMENDATIONS

Recommendations made by guideline panel members based on evidence for all factors.



What do these guidelines cover?

- 10 recommendations focused on red cell antigen typing and matching, indications and mode of administration (simple versus red cell exchange), as well as screening, prevention and management of alloimmunization, DHTRs and iron overload
- 9 recommendations were conditional
 - paucity of direct, high-certainty evidence for outcomes of interest
- Several recommendations have moderate resource implications given the cost of transfusion and the requirement for exchange transfusion in certain patient scenarios

How can we prevent alloimmunization and delayed hemolytic transfusion reactions?



Recommendation on red cell antigen typing

The panel suggests an extended red cell antigen profile by genotype or serology over only ABO/RhD typing for all patients with SCD (all genotypes) at the earliest opportunity (optimally prior to first transfusion) (conditional recommendation, very low certainty in the evidence about effects)

- Includes C/c, E/e, K, Jk^a/Jk^b, Fy^a/Fy^b, M/N, and S/s at a minimum
- Red cell antigen profiles should be made available across hospital systems
- A serologic phenotype may be inaccurate if transfused in the past 3 months
- Genotyping is preferred for the additional antigen information and increased accuracy for, among other things, C antigen determination and Fyb antigen matching



Rationale

The extended red cell antigen profile

- Needs to be performed only once
- Reduces alloimmunization when used to antigen match patients with blood donors
- Expedites antibody identification and aids donor unit selection when a patient requiring transfusion presents with a positive antibody screen

Genotyping assays for blood group antigens

- Extended red cell antigen profile
 - <u>H</u>uman <u>E</u>rythrocyte <u>A</u>ntigen (HEA) provides DNA predicted status on > 30 antigens, and is FDA-approved test of record
 - Identifies the "GATA" mutation in *DARC* gene that results in loss of Duffy antigen expression, specifically in red cells
- Higher resolution or comprehensive *RH* genotyping that identifies Rh variants
 - Hybrid RHD*DIIIa-CE(4-7)-D allele
 - Type C+ with common serologic assays
 - Prophylactic C- units indicated if no conventional RHCE*Ce or *CE





Recommendation on red cell antigen matching

The panel recommends prophylactic red cell antigen matching for Rh (C, E or C/c, E/e) and K antigens over only ABO/RhD matching for patients with SCD (all genotypes) receiving transfusions (*strong recommendation, moderate certainty in the evidence about effects*)

- Extended red cell antigen matching (Jk^a/Jk^b, Fy^a/Fy^b, S/s) may provide further protection from alloimmunization, but finding compatible units can be challenging
- Patients that have a GATA mutation in the ACKR1 gene, which encodes Fy antigens, are not at risk of anti-Fy^b and do not require Fy^b negative red cells
- Patients identified by genotype with the hybrid RHD*DIIIa-CE(4-7)-D or RHCE*CeRN alleles, which encode partial C antigen, and no conventional RHCE*Ce or *CE allele should be transfused with C negative red cells to prevent allo-anti-C development



Rationale

- Alloimmunization incidence in patients with SCD is the HIGHEST of any transfused patient population
- Transfusion burden, inflammation, and RH genetic diversity play a role
- Prevention of antibody formation may avoid hemolytic transfusion reactions, difficulty in identifying sufficient antigen-negative units and transfusion delays



Evidence

When the data were pooled from single arm studies, a significantly lower alloimmunization incidence rate was noted with Rh, K or extended matching vs. ABO/D matching alone:

- Rh (C/E or C/c, E/e) and K matched: **0.40** per 100 units transfused
- Extended matched: **0.25** per 100 units transfused
- ABO/D matched: 1.94 per 100 units

author,	Rate per 100	
rear	transfusion (95% CI)	
ABO/D only		
Ambruso, 1987	3.46 (3.29, 3.62)	
Boateng, 2014	3.13 (3.04, 3.21)	
Castro, 2002	3.83 (3.79, 3.87)	
Godfrey, 2010	• 0.19 (0.17, 0.21)	
Sakhalkar, 2005	1.68 (1.66, 1.70)	
Vichinsky 1990	3.92 (3.82, 4.01)	
Subtotal (I-squared = 100.0%, p = 0.000)	1.94 (1.28, 2.94)	
Extended		
Ambruso, 1987	• 0.30 (0.27, 0.33)	
Kalff, 2010.	• 0.88 (0.85, 0.91)	
LaSalle-Williams, 2011	0.10 (0.09, 0.11)	
Tahhan, 1994	0.00 (0.00, 0.01)	
Yee, 2017	• 0.30 (0.28, 0.32)	
Subtotal (I-squared = 99.9%, p = 0.000)	0.25 (0.09, 0.71)	
Extended or CEK		
Boateng, 2014	• 0.94 (0.88, 0.99)	
Subtotal (I-squared = $.\%$, p = .)	0.94 (0.88, 0.99)	
	•	
CEK		
Chou, 2013	• 0.30 (0.29, 0.30)	
Debaun, 2014	• 0.28 (0.26, 0.30)	
Godfrey, 2010	0.05 (0.05, 0.06)	
Hamideh, 2015	1.58 (1.51, 1.64)	
Master, 2016	1.16 (1.13, 1.19)	
Roberts, 2012	0.00 (0.00, 0.01)	
Sakhalkar, 2005	• 0.25 (0.23, 0.28)	
Sins, 2016	• 0.86 (0.85, 0.88)	
Vichinsky, 2001	• 0.55 (0.51, 0.58)	

.01 .1 .3 .5 1 3 5



Other considerations

Despite serologic matching for Rh (D, C, E or D, C/c, E/e) antigens, patients remain at risk of forming alloantibodies to the Rh system due to the increased prevalence of *RH* variants in this patient population

Anti-Rh antibody formed despite Rh (D, C, E or D, C/c, E/e) matched transfusions Comprehensive RH genotyping at a reference immunogenomics laboratory

Rh variants contribute to alloimmunization

RhD



RhCE



Partial e+, partial c+

- Variant alleles may encode partial antigens, cause loss of high prevalence antigens and/or generate novel antigens
- Serologic Rh typing detects the five principal antigens and do not reliably distinguish Rh variants

What to do when a delayed hemolytic transfusion reaction occurs



Defining DHTRs and/or hyperhemolysis

- DHTR is defined as a significant drop in hemoglobin within 21 days post-transfusion associated with one or more of the following:
 - new red cell alloantibody
 - hemoglobinuria
 - accelerated HbS% increase with a concomitant fall in HbA% post-transfusion
 - relative reticulocytopenia or reticulocytosis from baseline
 - significant LDH rise from baseline
 - exclusion of an alternative cause
- Hyperhemolysis is defined as a rapid hemoglobin decline to below the pretransfusion level and rapid decline of the post-transfusion HbA% level



Recommendation for management of DHTR

The panel suggests immunosuppressive therapy (IVIg, steroids, rituximab, and/or eculizumab) over no immunosuppressive therapy in patients with SCD (all genotypes) with a delayed hemolytic transfusion reaction and ongoing hyperhemolysis (conditional recommendation, very low certainty in the evidence about effects)

- Immunosuppressive therapy should be initiated promptly in patients with life-threatening hemolysis
- The potential harm of not providing immunosuppressive therapy to an individual experiencing a DHTR with ongoing hyperhemolysis is possible but unpredictable



Recommendation continued

- First-line: IVIg and high-dose steroids
- Second-line: eculizumab
- Rituximab is primarily indicated for potential prevention of additional alloantibody formation in patients who may require further transfusion
- When no antibody specificity is identified, avoidance of further transfusion is recommended unless patients are experiencing life-threatening anemia
 - If transfusion is warranted, consider extended matched red cells (C/c, E/e, K, Jk^a/Jk^b, Fy^a/Fy^b, S/s)

How do we prevent a delayed hemolytic transfusion reaction in a high risk patient?



Rare clinical situations in which patients:

- are experiencing life-threatening anemia that require immediate red cell transfusion and compatible blood cannot be found (i.e., patients with alloantibodies for whom antigen-negative blood is unavailable)
- have a history of repeated episodes of severe hemolytic transfusion reactions with or without an antibody specificity identified (even when compatible blood is available)



Recommendation to prevent DHTRs in at risk patients

The panel suggests immunosuppressive therapy (IVIg, steroids, and/or rituximab) over no immunosuppressive therapy in patients with SCD (all genotypes) with an acute need for transfusion and at high risk of acute hemolytic transfusion reaction or with a history of multiple reactions (conditional recommendation, very low certainty in the evidence about effects)

- Ongoing discussion is needed to weigh the potential benefits and harms associated with transfusion versus the impact of ongoing life-threatening anemia
- Consider the respective mechanisms of action for choice of therapy (IVIg, steroids, and/or rituximab)
- A shared decision-making process is critical



Considerations

- The morbidity and mortality associated with acute and delayed HTRs is weighed against the potential adverse effects typically experienced with immunosuppression
- Interventions aimed at inhibiting antibody-mediated hemolysis (i.e., IVIg and steroids) may be more effective in preventing a potential AHTR
- Efforts to prevent DHTR may benefit from immunosuppression that mitigates new alloantibody production (i.e., steroids, rituximab)

Approach to transfusions in chronic and acute settings



Recommendation for pre-operative transusion

The panel suggests preoperative transfusion over no preoperative transfusion in patients with SCD undergoing surgeries requiring general anesthesia and lasting >1 hour (conditional recommendation, very low certainty in the evidence about effects)

- Decision-making should be individualized based on:
 - genotype
 - the risk level of surgery
 - baseline total hemoglobin
 - complications with prior transfusions
 - disease severity
- Ideal to have total hemoglobin levels of >9 g/dl prior to surgery, and should provide RCE transfusion for patients who require preoperative transfusion but have a high hemoglobin level (>9-10 g/dl)



Rationale

- Surgical intervention results in:
 - increased mortality and morbidity in patients with SCD who undergo surgery
 - increased risk of postoperative pain crisis and ACS
- Treating with preoperative blood transfusion reduces the risks of postoperative complications
- Most beneficial in patients who are:
 - undergoing high-risk surgery (cardiac surgery or neurosurgery), patients with a low preoperative hemoglobin level (<9 g/dl), and patients with a more severe genotype (HbSS/HbSB^othal) or phenotype
- Less beneficial in patients who are:
 - undergoing low-risk surgery, patients with a higher hemoglobin level (>10 g/dl) or HbF level, or those with a milder genotype (HbSC) or phenotype



Recommendation for chronic transfusion modality

The panel suggests using automated RCE over simple transfusion or manual RCE in patients with SCD (all genotypes) receiving chronic blood transfusions *(conditional recommendation, very low certainty in the evidence about effects)*

 Consideration should be given to the clinical indication, baseline and target total hemoglobin and HbS%, patient age, patient preferences (particularly if central venous access is needed), iron overload status and iron chelation compliance, feasibility, and availability of compatible red cells



Evidence*

- 14 comparative observational studies (total, 652 patients)
 - nine studies compared automated RCE to simple transfusion
 - six studies compared automated RCE to manual RCE
- compared to simple transfusion, automated RCE was associated with increased red cell unit requirement but was not associated with increased alloimmunization or adverse transfusion reactions
- automated RCE was associated with lower levels of iron overload
- automated RCE increased the odds of achieving the desired pre-procedure HbS with shorter procedure duration and increased intervals between procedures

* the certainty of evidence was judged to be very low, due to imprecision, inconsistency, and/or high risk of bias



Considerations for mode of chronic transfusion therapy

Simple transfusion	Manual red cell exchange	Automated red cell exchange
Peripheral venous access	+/- indwelling central catheter	+/- indwelling central catheter
Fewest red cell exposures	Intermediate red cell exposures	Highest red cell exposures
Iron loading inevitable	Intermediate iron loading	Minimal iron loading
Potential circulatory overload	Minimizes blood volume shifts	Maintains isovolemia
Potential hyperviscosity	Requires trained personnel	Requires specialized device and personnel

Simple transfusion may be preferred over RCE for:

- Young patients with small total blood volume
- Highly alloimmunized patients (availability of red cell units)
- Patients who would require an indwelling catheter



Recommendations for acute chest syndrome

The panel suggests automated RCE or manual RCE over simple transfusions in patients with SCD and severe acute chest syndrome (conditional recommendation, very low certainty in the evidence about effects)

• RCE for rapidly progressive ACS, not responding to initial treatment with simple transfusion, or with high pre-transfusion hemoglobin level that precludes simple transfusion

The panel suggests either automated RCE, manual RCE or simple transfusions in patients with SCD and moderate acute chest syndrome (conditional recommendation, very low certainty in the evidence about effects)

 insufficient evidence to support automated RCE or manual RCE over simple transfusions in patients with SCD and moderate ACS



Rationale

- The guideline panel determined that there is very low certainty of evidence for a net health benefit <u>or harm</u> of RCE compared to simple transfusion to treat moderate or severe ACS
- Data limited with few publications, relatively few episodes of ACS that occurred mostly children, and a high likelihood of indication bias
- Although no evidence of benefit from RCE was identified, this does not imply that such an effect does not exist
- Automated RCE can reduce HbS levels more rapidly than manual RCE



Recommendation for pregnancy

The guideline panel suggests either prophylactic transfusion at regular intervals or standard care (transfusion when clinically indicated for a complication or hemoglobin lower than baseline) for pregnant patients with SCD (all genotypes) (conditional recommendation, very low certainty in the evidence about the effects)

- insufficient evidence to recommend a strategy of prophylactic transfusion rather than standard care
- consider prophylactic transfusion at regular intervals at the onset of pregnancy when:
 - history of severe SCD-related complications prior to current pregnancy to reduce recurrent pain episodes, acute chest syndrome or other (SCD-related) comorbidities
 - additional features of high-risk pregnancy



Rationale

- Pregnancy in SCD is associated with:
 - maternal and fetal morbidity and mortality
 - inflammatory and thrombogenic changes that promote vaso-occlusion
 - higher rate of SCD-related complications, including pain episodes, ACS, and death
 - increased risk of pregnancy-related complications, such as pre-eclampsia and miscarriage
 - increased rate of fetal complications, including low birth weight, small size for gestational age, and stillbirth
- Hydroxyurea is teratogenic in animal models at high doses



Evidence*

- 12 comparative observational studies and one randomized control trial (RCT) (total, 1312 patients)
- RCT of scheduled vs on-demand transfusions (n=72)*
 - Reduced odds of pain episodes in scheduled transfusion arm
 - No difference in fetal complications or neonatal death
 - Limitations: transfusions did not begin until end of second trimester for ~25% of participants, and 44% of on demand transfusion arm required transfusions for acute anemia
- Based on a lack of high-quality studies and limited data regarding the potential complications of transfusion in pregnancy, the guideline panel did not recommend prophylactic, scheduled transfusion over on-demand transfusion in pregnant women with SCD

* the certainty of evidence was judged to be very low, due to imprecision, inconsistency, and/or high risk of bias * Koshy et al, NEJM, 1988



Additional Topics in the Guidelines

- The guideline panel suggests *either* red cell exchange with isovolemic hemodilution or conventional RCE in patients with SCD receiving chronic transfusions (conditional recommendation)
- The guideline panel suggests iron overload screening by magnetic resonance imaging (MRI; R2, T2*, R2*) for liver iron content every 1 to 2 years compared to serial monitoring of ferritin levels alone in patients with SCD receiving chronic transfusion therapy (conditional recommendation)
- The guideline panel suggests against adding routine iron overload screening by T2* MRI for cardiac iron content compared with serial monitoring of ferritin levels alone in patients with SCD receiving chronic transfusion therapy (conditional recommendation)

Acknowledgments

Mouaz Alsawas Ross M. Fasano Joshua J. Field Jeanne E. Hendrickson Jo Howard Michelle Kameka Janet Kwiatkowski **France Pirenne** Patricia A. Shi Sean R. Stowell Swee Lay Thein Connie M. Westhoff Trisha E. Wong Elie A. Akl

ASH Staff, Starr Webb

ASH Pocket Guides



ASH Clinical Practice Guidelines

Q 📣 Cardiopulmonary Disease Cerebrovascular Disease Management of Acute and Chronic Pain Transfusion Support Additional SCD Guideline Tools

Ahmar U. Zaidi, Children's Hospital of Michigan who co-developed the ASH guideline teaching slides